Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed the day trading at $0.98 up 17.48% from the previous closing price of $0.84. In other words, the price has increased by $17.48 from its previous closing price. On the day, 1.35 million shares were traded. IRWD stock price reached its highest trading level at $0.9872 during the session, while it also had its lowest trading level at $0.8401.
Ratios:
For a better understanding of IRWD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.33. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 0.82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when John Minardo bought 8,281 shares for $0.88 per share.
Martini Gregory S. bought 1,351 shares of IRWD for $1,189 on Aug 11 ’25. On Aug 11 ’25, another insider, Gaskins Tammi L, who serves as the Officer of the company, bought 1,406 shares for $0.88 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 159591408 and an Enterprise Value of 664709824. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.52. Its current Enterprise Value per Revenue stands at 2.155 whereas that against EBITDA is 7.065.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.30, which has changed by -0.7741935 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.20, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 31.79%, while the 200-Day Moving Average is calculated to be -51.73%.
Shares Statistics:
Over the past 3-months, IRWD traded about 2.22M shares per day on average, while over the past 10 days, IRWD traded about 1596880 shares per day. A total of 162.43M shares are outstanding, with a floating share count of 155.76M. Insiders hold about 3.74% of the company’s shares, while institutions hold 98.53% stake in the company. Shares short for IRWD as of 1753920000 were 5382745 with a Short Ratio of 2.43, compared to 1751241600 on 7475343. Therefore, it implies a Short% of Shares Outstanding of 5382745 and a Short% of Float of 5.050000000000001.
Earnings Estimates
The current rating of Ironwood Pharmaceuticals Inc (IRWD) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.11, with high estimates of $0.11 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.21 and $0.21 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.21, with 3.0 analysts recommending between $0.4 and $0.0.
Revenue Estimates
5 analysts predict $74.22M in revenue for the current quarter. It ranges from a high estimate of $83.4M to a low estimate of $68.4M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $91.59MFor the next quarter, 5 analysts are estimating revenue of $76.4M. There is a high estimate of $84M for the next quarter, whereas the lowest estimate is $70M.
A total of 5 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $275.2M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $272.3M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $258.84M in the next fiscal year. The high estimate is $285M and the low estimate is $225.8M.
